domenica, Dicembre 22, 2024

Kampferolo per la riprogrammazione cellulare nelle allergie: ma con un meccanismo d’azione alternativo

Malattie allergiche come asma, dermatite atopica e allergie alimentari...

Microbiota urinario: il regolatore della formazione dei calcoli renali e possibilmente di altre condizioni

I ricercatori della Cleveland Clinic hanno trovato la prova...

Dread DNA modification? Fear not, anxiety is now an option

Researchers at The University of Queensland have discovered a DNA modification that enhances our ability to extinguish fear. Fear extinction works as a counter-balance to fear and involves the creation of new non-fearful memories with similar environmental elements that compete with the original fear memory. The findings, published in the journal Nature Neuroscience, could help guide the development of new treatments for fear-related anxiety disorders. Professor Timothy Bredy of UQ’s Queensland Brain Institute (QBI) said while fear is an important survival mechanism which uses cues in the environment to prompt certain responses, so too is the ability to inhibit fear when it’s no longer needed. Professor Bredy said the balance between fear and fear-extinction is critical to cognitive flexibility, enabling the brain to rapidly adapt to changing conditions. Meanwhile, impairment in fear extinction is a key feature in both post-traumatic stress disorder (PTSD) and phobias.

He and his team, including Dr Xiang Li, have now discovered how these chemical tags help regulate fear extinction: “You still want to have that memory of ‘there’s something dangerous there, I want to be careful,’ but you don’t want it to compromise your ability to function normally. Chemical tags on DNA bases act like a dimmer switch that can turn up or turn down the expression of a gene without affecting the underlying DNA sequence. For a long time, it was thought that only one DNA base – cytosine – could be modified, and that these chemical changes in the brain reduce gene expression. We have now discovered that adenosine, another DNA base, can also be chemically tagged, and that fear extinction memories form thanks to a deoxyadenosine (or adenine) modification that increases the activity of certain genes.”

The researchers made the discovery by placing mice in a box where they heard a particular tone, which was immediately followed by a mild foot-shock; the mice quickly associated the sound with the foot-shock and froze when they heard it. To encourage fear extinction, the mice were then placed in a different box, where they repeatedly heard the same sound, but did not receive any foot-shocks. When the mice were returned to the original box, they were no longer afraid of the sound. The researchers examined the DNA from those mice, particularly the DNA from neurons known to be involved in the fear extinction process. In so doing, they discovered the presence of a modified deoxyadenosine (or adenine) at more than 2800 locations across the genomes of those neurons. They found that this change only occurs during the fear extinction process. In particular, the team discovered an adenosine modification in a gene called brain-derived neurotrophic factor (BDNF), which is known to nurture learning and memory.

Interestingly, the modification appears to increase levels of BDNF during fear extinction. To confirm the importance of the deoxyadenosine (or adenine) modification to fear extinction, scientists switched off the gene responsible for making the modification in a group of mice, then repeated the experiment. The mice learned to fear the sound of the tone, but they were unable to form fear extinction memories. Ultimately, both Professor Bredy and Dr Li want to understand the full picture of how fear extinction memory is formed and stored in the brain: “This work is an important step toward that and toward finding effective treatments for a variety of psychiatric disorders. Understanding the fundamental mechanism of how gene regulation associated with fear extinction could provide future targets for therapeutic intervention in fear-related anxiety disorders”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Li X, Zhao Q et al., Bredy TW. Nat Neurosci. 2019 Feb 18. 

Li X et al., Wei W. J Neurosci. 2019 Feb 6; 39(6):970-983.

Marshall PR et al. Psychopharmacology 2019; 236(1):133. 

Latest

Newsletter

Don't miss

Dott. Gianfrancesco Cormaci
Dott. Gianfrancesco Cormaci
Laurea in Medicina e Chirurgia nel 1998; specialista in Biochimica Clinica dal 2002; dottorato in Neurobiologia nel 2006; Ex-ricercatore, ha trascorso 5 anni negli USA (2004-2008) alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. Medico penitenziario presso CC.SR. Cavadonna (SR) Si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

Battaglia al carcinoma triplo-negativo con attacco alle protein-chinasi: le scoperte su DAPK3

Il carcinoma mammario triplo negativo (TNBC) è il sottotipo di tumore al seno più difficile da trattare. Le pazienti con TNBC rappresentano oltre 20.000...

Farmaci comuni: sovvertono il microbiota con rischi potenziali

Il tratto gastrointestinale umano ospita enormi colonie di batteri e altri microrganismi, definiti collettivamente il microbiota intestinale. Questa vasta e variegata comunità microbica si...

Uveite: dai tumori forse il farmaco anti-infiammatorio perfetto

Si stima che l'uveite rappresenti il ​​10% di tutti i casi di cecità negli Stati Uniti, compresi 30.000 nuovi casi di cecità legale ogni...

Questo si chiuderà in 20 secondi